1. Home
  2. ATNM vs BRFH Comparison

ATNM vs BRFH Comparison

Compare ATNM & BRFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • BRFH
  • Stock Information
  • Founded
  • ATNM 2000
  • BRFH 2005
  • Country
  • ATNM United States
  • BRFH United States
  • Employees
  • ATNM N/A
  • BRFH N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • BRFH Packaged Foods
  • Sector
  • ATNM Health Care
  • BRFH Consumer Staples
  • Exchange
  • ATNM Nasdaq
  • BRFH Nasdaq
  • Market Cap
  • ATNM 46.5M
  • BRFH 50.9M
  • IPO Year
  • ATNM N/A
  • BRFH N/A
  • Fundamental
  • Price
  • ATNM $1.61
  • BRFH $3.05
  • Analyst Decision
  • ATNM Strong Buy
  • BRFH Strong Buy
  • Analyst Count
  • ATNM 4
  • BRFH 1
  • Target Price
  • ATNM $8.75
  • BRFH $4.50
  • AVG Volume (30 Days)
  • ATNM 1.3M
  • BRFH 15.1K
  • Earning Date
  • ATNM 04-25-2025
  • BRFH 03-27-2025
  • Dividend Yield
  • ATNM N/A
  • BRFH N/A
  • EPS Growth
  • ATNM N/A
  • BRFH N/A
  • EPS
  • ATNM N/A
  • BRFH N/A
  • Revenue
  • ATNM $81,000.00
  • BRFH $10,717,000.00
  • Revenue This Year
  • ATNM $138.42
  • BRFH $51.72
  • Revenue Next Year
  • ATNM $16,957.05
  • BRFH $38.85
  • P/E Ratio
  • ATNM N/A
  • BRFH N/A
  • Revenue Growth
  • ATNM N/A
  • BRFH 31.87
  • 52 Week Low
  • ATNM $1.03
  • BRFH $1.03
  • 52 Week High
  • ATNM $10.24
  • BRFH $4.61
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 59.52
  • BRFH 38.69
  • Support Level
  • ATNM $1.66
  • BRFH $3.22
  • Resistance Level
  • ATNM $2.41
  • BRFH $3.80
  • Average True Range (ATR)
  • ATNM 0.22
  • BRFH 0.36
  • MACD
  • ATNM 0.05
  • BRFH -0.05
  • Stochastic Oscillator
  • ATNM 37.60
  • BRFH 16.67

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About BRFH Barfresh Food Group Inc.

Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.

Share on Social Networks: